Jan 06, 2025
Merck KGaA, Darmstadt, Germany, launches first-to-market, cyber-physical trust platform to tackle issues of product safety and counterfeiting
Jan 20, 2021
Merck KGaA, Darmstadt, Germany Announces Update on the INTR@PID Clinical Program Including Lung 037 Study
Nov 20, 2020
Massachusetts-based Businesses of Merck KGaA, Darmstadt, Germany Named to The Boston Globe's 'Top Places to Work' List
Nov 17, 2020
Merck KGaA, Darmstadt, Germany to deploy Insilico Medicine's Chemistry42 AI platform for generative chemistry
Dec 04, 2019
Ping An Good Doctor and Merck KGaA, Darmstadt, Germany Form Strategic Collaboration to Advance Intelligent Healthcare in China
May 22, 2019
Experts Discuss Decentralized Manufacturing to Tackle Neglected Tropical Diseases and Promote Universal Health Coverage at World Health Assembly Event
May 06, 2019
Intermolecular to be acquired by Merck KGaA, Darmstadt, Germany for $1.20 per share in an all cash transaction
Feb 06, 2019
Merck KGaA, Darmstadt, Germany to Expand US Biopharmaceutical R&D Facility to Advance Innovative Clinical Pipeline
Jan 24, 2019
Merck KGaA, Darmstadt, Germany, Grants Exclusive License to Vertex for Two DNA Damage Response Inhibitors
Dec 20, 2018
Merck KGaA, Darmstadt, Germany, Assigns Chimeric Antigen Receptor T-cell (CAR-T) Rights to Intrexon
Dec 06, 2018
Merck KGaA, Darmstadt, Germany, in Agreement with Cyclica for AI-augmented Screening Platform to Expand Research Capabilities
Nov 19, 2018
Syntropy to Unlock the Value of Scientific Data in Fight to End Cancer
Nov 06, 2018
Embracing Carers(TM) expands support for caregivers worldwide
Oct 22, 2018
Merck KGaA, Darmstadt, Germany, Presents Updated Results for Bifunctional Immunotherapy M7824 at ESMO 2018 Congress
Oct 12, 2018
Positive Late-Breaking Phase II Data Evaluating Investigational Oral Therapy, Evobrutinib in RMS
Oct 09, 2018
Merck KGaA, Darmstadt, Germany Data at ESMO 2018 Congress Highlight Multiple Therapeutics with Potential to Transform Cancer Care
Oct 03, 2018
Merck KGaA, Darmstadt, Germany Selects ArcherDX for Strategic Global Companion Diagnostic Assay Development Collaboration
Sep 11, 2018
BAVENCIO® (avelumab) Plus INLYTA® (axitinib) Significantly Improved Progression-Free Survival in Previously Untreated Patients With Advanced Renal Cell Carcinoma in Phase III Study
Jun 11, 2018
Merck KGaA, Darmstadt, Germany Provides Update on Tepotinib Phase II Results in Advanced Hepatocellular Carcinoma
Jun 04, 2018
Merck KGaA, Darmstadt, Germany Presents Updated Clinical Results for Bifunctional Immunotherapy M7824 at ASCO 2018